Senior Director, Health Economics & Outcomes Research; HEOR

Bio Marin is a leading rare disease biotechnology company focused on genetically defined conditions.

Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options.

More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.

Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of Bio Marin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.

Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies Bio Marin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

The Health Economics & Outcomes Research (HEOR) Senior Director leads asset‑specific payer evidence strategies, including patient‑relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for Bio Marin assets across all therapeutic areas of interest. s. The role is responsible for shaping patient‑relevant outcomes requirements within the clinical programs, ensuring alignment with Regulatory, HTA and access needs.

In partnership with internal cross‑functional and external stakeholders, the Senior Director leads the design and execution of patient‑relevant outcomes research initiatives.

The Sr. Director cultivates strong partnerships with cross‑functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while engaging with external stakeholders including HTA agencies, payers and patient organizations. This role requires deep expertise in patient‑relevant outcomes research and a strong understanding of market access, value and HTA frameworks.

The position reports to the ED, Head of the Global HEOR team, which sits within the Pricing Access Value & Evidence (PAVE) organization and has a direct report.

• Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early‑stage pipeline assets
• Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
• Drive organizational understanding of payer and HTA requirements related to patient‑relevant outcomes and health utility measurement
• Drive the strategic assessment for patient‑relevant outcomes requirements for HTA and access to support differentiation and value demonstration
• Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
• Lead the development of cross‑functionally aligned, asset‑specific patient‑relevant outcomes strategies informed by disease conceptual models
• Lead patient‑relevant endpoint planning and provide oversight of implementation within clinical trials
• Lead early Joint Clinical Assessment (JCA) strategy development,…